Fungal Infections in Left Ventricular Assist Device Recipients

Goldstein, Daniel J.; El-Amir, Nabeel G.; Ashton, Robert C.; Catanese, Katharine A.; Rose, Eric A.; Levin, Howard R.; Öz, Mehmet C.

doi:10.1097/00002480-199510000-00010

Cited by 56 publications

(23 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a current case series, 62 85% of LVAD infections occurred when the device was left in place for Ͼ2 weeks. The incidence of infection has been highly variable among different surveys [63][64][65][66][67][68][69][70][71][72][73][74][75] and has been reported to range between 13% and 80%. The wide variability in infection risk is, in part, due to different types of infections that have been included under the category of LVAD-related infections.…”

Section: Left Ventricular Assist Devicesmentioning

confidence: 99%

Nonvalvular Cardiovascular Device–Related Infections

Baddour¹,

Bettmann²,

Bolger³

et al. 2003

Circulation

438

326

View full text Add to dashboard Cite

Section: Left Ventricular Assist Devicesmentioning

confidence: 99%

Nonvalvular Cardiovascular Device–Related Infections

Baddour¹,

Bettmann²,

Bolger³

et al. 2003

Circulation

438

326

View full text Add to dashboard Cite

“…Summary of prophylaxis recommendations [1]. [ [101][102][103]. The most likely offending organism in VADpatients is Candida, with an incidence of 28-55% [102,103].…”

Section: Heart Transplantmentioning

confidence: 99%

Invasive fungal infections and antifungal therapies in solid organ transplant recipients

et al. 2007

View full text Add to dashboard Cite

Summary This manuscript will review the risk factors, prevalence, clinical presentation, and management of invasive fungal infections (IFIs) in solid organ transplant (SOT) recipients. Primary literature was obtained via MEDLINE (1966–April 2007) and EMBASE. Abstracts were obtained from scientific meetings or pharmaceutical manufacturers and included in the analysis. All studies and abstracts evaluating IFIs and/or antifungal therapies, with a primary focus on solid organ transplantation, were considered for inclusion. English‐language literature was selected for inclusion, but was limited to those consisting of human subjects. Infectious complications following SOT are common. IFIs are associated with high morbidity and mortality rates in this patient population. Determining the best course of therapy is difficult due to the limited availability of data in SOT recipients. Well‐designed clinical studies are infrequent and much of the available information is often based on case‐reports or retrospective analyses. Transplant practitioners must remain aware of their therapeutic options and the advantages and disadvantages associated with the available treatment alternatives.

show abstract

“…4 -9 In fact, prophylactic use of antifungal therapy has been advocated in selected LVAD recipients to reduce the risk of fungal infection. 4 The high prevalence of fungal infection in LVAD recipients raises the possibility that LVAD implantation may be associated with the development of defects in host immunity.…”

mentioning

confidence: 99%

Quantitative Changes In T-Cell Populations After Left Ventricular Assist Device Implantation : Relationship to T-Cell Apoptosis and Soluble CD95

Ankersmit¹,

Edwards²,

Schuster³

et al. 1999

Circulation

View full text Add to dashboard Cite

Background-Left ventricular assist devices (LVADs) are currently being evaluated as permanent therapy for end-stage heart failure. Because life-threatening infections limit successful long-term device implantation, we investigated the relationship between quantitative T-cell defects in LVAD recipients and CD95-mediated T-cell apoptosis. Methods and Results-Immunological studies were performed in NYHA class IV patients awaiting cardiac transplantation who received either a TCI Heartmate left ventricular assist device (LVAD) or medical management. Fluorochromelabeled Mabs were used in T-cell phenotypic analyses. T-cell apoptosis was measured by annexin V binding of T cells cultured in medium for 24 hours. Circulating serum levels of soluble CD95 were measured by ELISA. LVAD recipients had a relative lymphopenia and reduction in CD4 T-cell levels compared with NYHA class IV heart failure controls. These observations were confirmed in a longitudinal study in LVAD recipients, which showed that device implantation was accompanied by progressive and sustained reductions in circulating CD4 T-cell levels. These abnormalities in LVAD recipients were accompanied by increased levels of circulating soluble CD95 and by excessive CD4 and CD8 T-cell apoptosis. Susceptibility to induction of apoptosis was Ͼ2-fold greater for CD4 T cells than for CD8 T cells. Conclusions-These

show abstract

Fungal Infections in Left Ventricular Assist Device Recipients

Cited by 56 publications

References 0 publications

Nonvalvular Cardiovascular Device–Related Infections

Nonvalvular Cardiovascular Device–Related Infections

Invasive fungal infections and antifungal therapies in solid organ transplant recipients

Quantitative Changes In T-Cell Populations After Left Ventricular Assist Device Implantation : Relationship to T-Cell Apoptosis and Soluble CD95

Contact Info

Product

Resources

About